Nivolumab Suppliers & Bulk Manufacturers
Available Forms: Intravenous (IV)
Available Strengths: 40 mg/4 mL (vial); 100 mg/10 mL (vial)
Reference Brands: Opdivo® (EU & US)
Category: Oncology Cancer Care
Nivolumab (brand name Opdivo®) is a monoclonal antibody used in oncology to treat various cancers by blocking the PD-1 receptor, which enhances the immune system’s ability to fight cancer. It is used for melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), head and neck cancers, and more. Nivolumab is available in intravenous (IV) form in strengths of 40 mg/4 mL and 100 mg/10 mL. It is available in both the US and EU. Nivolumab is available in Intravenous (IV) and strengths such as 40 mg/4 mL (vial); 100 mg/10 mL (vial). Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Nivolumab is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Nivolumab can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
Product Description:
Nivolumab (brand name Opdivo®) is a monoclonal antibody used in oncology as an immune checkpoint inhibitor. It works by targeting and blocking the PD-1 receptor on T-cells, which prevents cancer cells from evading the immune system. By doing so, Nivolumab enhances the body's immune response, allowing T-cells to identify and attack cancer cells more effectively. Nivolumab is indicated for the treatment of several cancers, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), head and neck squamous cell carcinoma, classical Hodgkin lymphoma, and others. It is administered as an intravenous (IV) infusion in two available strengths: 40 mg/4 mL and 100 mg/10 mL.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Nivolumab is used in the treatment of various types of cancer, including melanoma, non–small cell lung cancer (NSCLC), renal cell carcinoma, classical Hodgkin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, and colorectal cancer. It works as an immune checkpoint inhibitor by blocking the PD-1 receptor, thereby enhancing the immune system’s ability to detect and destroy cancer cells.
Nivolumab is a fully human IgG4 monoclonal antibody produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. It specifically binds to the programmed death-1 (PD-1) receptor on T cells to inhibit its interaction with PD-L1 and PD-L2.
The trade name of Nivolumab is Opdivo.
Nivolumab (Opdivo) is developed and manufactured by Bristol Myers Squibb (BMS).
The generic name is Nivolumab.
The brand name is Opdivo.
Nivolumab is manufactured by Bristol Myers Squibb at its biopharmaceutical production facilities in the United States and Europe, including facilities in Devens (Massachusetts, USA) and Cruiserath (Ireland).
Related Products
Tafasitamab‑Cxix
Strength:
200 mg
Form: Injection
Reference Brands: Monjuvi (USA), Minjuvi (EU)
View Details
Dordaviprone Hydrochloride
Strength:
125 mg
Form: Capsules
Reference Brands: Modeyso (USA)
View Details
Quick Response Guaranteed | Verified Suppliers
